
    
      This is a phase 2 study of the combination of docetaxel and carboplatin in patients with
      germline inactivation of genes in the homologous recombination pathway, including BRCA1,
      BRCA2, and ATM.

      PRIMARY OBJECTIVE To assess rate of 50% Prostate Specific Androgen (PSA) decline to docetaxel
      and carboplatin
    
  